Outcomes of Sorafenib Therapy in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A 12-Year Single-Center Experience
Abstract
Objective: Differentiated thyroid cancer (DTC) generally has a favorable prognosis; however, resistance to radioactive iodine therapy (RAI) markedly worsens outcomes. Sorafenib is among the standard treatment options for RAI-refractory DTC. This study aimed to present our single-center experience with sorafenib therapy. Methods: The medical records of patients diagnosed with RAI-refractory DTC who were followed in the endocrinology and oncology outpatient clinics of Bursa Uludağ University Faculty of Medicine Hospital between 2010 and 2022 and treated with sorafenib were retrospectively reviewed. Progression-free survival (PFS), overall survival (OS), response rates, and adverse events profiles were analyzed. Results: Of the 19 patients included, 68.4% had papillary thyroid carcinoma and 31.6% had follicular variants. Median PFS was 16.1 months, and median OS was 36.2 months. The overall response rate was modest, while sorafenib-related adverse events occurred in 63% of patients, most commonly hand–foot syndrome (31%). Conclusion: Our single-center data suggest that sorafenib is a generally tolerable and effective therapeutic option in patients with RAI-refractory DTC, with median PFS exceeding 1 year despite frequent adverse events.
Keywords
Ethical Statement
References
- 1. WHO GLOBOCAN 2022 [cited 2025 Aug 5]. Available from: https://gco.iarc.who.int/.
- 2. Asa SL. The current histologic classification of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):1– 22. doi:10.1016/j.ecl.2018.10.001.
- 3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism. 2006;91(8):2892–9. doi:10.1210/jc.2005-2838.
- 4. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine. 2015;372(7):621–30. doi:10.1056/ NEJMoa1406470.
- 5. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 2014;384(9940):319–28. doi:10.1016/S0140-6736(14)60421-9.
- 6. Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, et al. 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35(8):841–985. doi:10.1177/10507256251363120.
- 7. NCCN. Thyroid Cancer 2025 [cited 2025 Oct 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
- 8. Oh HS, Shin DY, Kim M, Park SY, Kim TH, Kim BH, et al. Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study. Thyroid. 2019;29(12):1804–10. doi:10.1089/thy.2019.0246.
Details
Primary Language
English
Subjects
Endocrinology , Clinical Oncology
Journal Section
Research Article
Publication Date
February 28, 2026
Submission Date
November 20, 2025
Acceptance Date
January 20, 2026
Published in Issue
Year 2026 Volume: 8
